Comparative Pharmacology
Head-to-head clinical analysis: PROCAN SR versus PROCANBID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PROCAN SR versus PROCANBID.
PROCAN SR vs PROCANBID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Procainamide is a class Ia antiarrhythmic agent that blocks sodium channels, reducing myocardial excitability and conduction velocity, and prolonging the refractory period.
Class Ia antiarrhythmic agent; inhibits sodium channels, slowing conduction velocity, increasing effective refractory period, and suppressing automaticity.
Oral: 50 mg/kg/day divided every 6 hours; typical adult dose: 250-500 mg every 6 hours. For sustained-release (Procan SR): 500-1000 mg every 6 hours.
Procainamide extended-release (Procanbid) is dosed based on ideal body weight. Typical adult dose: 500 mg to 1500 mg orally every 12 hours. Maximum dose: 3000 mg/day. Dose should be titrated to achieve therapeutic plasma procainamide and NAPA levels.
None Documented
None Documented
Procainamide: 2.5-4.7 hours (normal renal function); NAPA: 6-8 hours. In renal impairment, half-life prolonged up to 10-20 hours for procainamide and 40+ hours for NAPA.
Terminal elimination half-life: 2.5-4.7 hours (procainamide) with normal renal function; clinical context: prolonged in renal impairment (up to 14 hours) and heart failure; NAPA half-life: 6-8 hours.
Renal: 50-60% as unchanged procainamide; hepatic metabolism to N-acetylprocainamide (NAPA) which is also renally excreted; total renal excretion of procainamide + NAPA accounts for ~85% of dose; remainder fecal (<5%).
Renal excretion: 50-60% unchanged; hepatic metabolism to N-acetylprocainamide (NAPA) with further renal elimination; total renal elimination of procainamide and NAPA >80%.
Category C
Category C
Class Ia Antiarrhythmic
Class Ia Antiarrhythmic